ABOUT MABVAX THERAPEUTICS
MabVax Therapeutics Holdings, Inc. is a clinical stage oncology drug development company focused on the development of human antibody-based products and vaccines to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines.
•MabVax has the exclusive license to therapeutic vaccines from Memorial Sloan Kettering Cancer Center. > Read more about our collaboration
•MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma that will be ready for Phase II clinical trial later this year. > Read more about our current clinical trials
LATEST NEWS & EVENTS
June 1-3, 2015
MabVax to present at LD Micro Conference.
Read More >
April 7, 2015
MabVax Therapeutics Appoints Tom Varvaro to its Board of Directors.
Read More >
April 6, 2015
MabVax Therapeutics Announces Closing of Financing.
HuMab 5B1 Program
MabVax's HuMab 5B1 antibody has demonstrated high specificity, affinity, and lack of cross re-activity with closely related antigens.
Phase 2 Sarcoma Study
Our sarcoma vaccine is currently in a proof of concept randomized, double blind, multi-center Phase II clinical trial.
Phase 2 Ovarian Study
Our ovarian vaccine is currently in a proof of concept randomized, double blind, multi-center Phase II clinical trial.
New video coming soon
Sign up for Email AlertsBe the first to get breaking news